Thursday, 5 November 2026European Markets

ELOPAK And SMURFIT KAPPA GP Have A High Dividend Yield And Return On Equity In The Packaging & Containers Industry.

Loading stream...

(VIANEWS) - ELOPAK (ELO.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Packaging & Containers industry.

Financial Asset Price Forward Dividend Yield Return on Equity
ELOPAK (ELO.OL) kr35.80 3.83% 22.46%
SMURFIT KAPPA GP (SK3.IR) €43.17 3.6% 14.31%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. ELOPAK (ELO.OL)

3.83% Forward Dividend Yield and 22.46% Return On Equity

Elopak ASA manufactures and supplies paper-based packaging solutions for liquid food in Europe, the Middle East, Africa, Asia, the Americas, and internationally. It offers Pure-Pak cartons for chilled and aseptic liquid food; common roll fed aseptic carton; D-PAK cartons for non food products for personal and home care; and filling equipment. It also offers standard flexo, super flexo, UV-flexo, and offset litho printing services, as well as digital print proofs and machine print proofs on paper board. Further, it provides machines and equipment through spare part webshop. Elopak ASA was founded in 1957 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, ELOPAK has a trailing twelve months EPS of kr3.07.

PE Ratio

ELOPAK has a trailing twelve months price to earnings ratio of 11.66. Meaning, the purchaser of the share is investing kr11.66 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 22.46%.

More news about ELOPAK.

2. SMURFIT KAPPA GP (SK3.IR)

3.6% Forward Dividend Yield and 14.31% Return On Equity

Smurfit Kappa Group Plc, together with its subsidiaries, manufactures, distributes, and sells containerboard, corrugated containers, and other paper-based packaging products in Ireland, Germany, France, Mexico, rest of Europe, and other Americas. The company offers e-commerce, retail, consumer, industrial, bottle, protective, heavy-duty, hexacomb, and various punnet packaging products; composite cardboard tubes, bags, and sacks; and bag-in-box, a packaging system that comprises films, accessories, bags, taps, and boxes. It also provides point of sale displays; cardboards of social distancing; corrugated sheet boards, solid board sheets, folding carton sheet boards, sack Kraft papers, MG brown Kraft papers, preprint products, agro-papers, technical papers, BanaBag, and Catcher Board MB12; and various types of containerboards, such as kraftliners, testliners, and containerboard flutings. In addition, the company offers recycling solutions to cardboard and paper products; and supplies packaging machinery. It primarily serves consumer goods, industrial goods, and food and drink sectors. Smurfit Kappa Group Plc was founded in 1934 and is headquartered in Dublin, Ireland.

Earnings Per Share

As for profitability, SMURFIT KAPPA GP has a trailing twelve months EPS of €2.91.

PE Ratio

SMURFIT KAPPA GP has a trailing twelve months price to earnings ratio of 14.84. Meaning, the purchaser of the share is investing €14.84 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.31%.

More news about SMURFIT KAPPA GP.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com